Diabetic foot ulcer - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Diabetic foot ulcer - Pipeline Insight, 2021,” report provides comprehensive insights about 34+ companies and 34+ pipeline drugs in Diabetic foot ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetic foot ulcer: Overview
A diabetic foot ulcer is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of diabetic foot ulcers requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.
'Diabetic foot ulcer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic foot ulcer pipeline landscape is provided which includes the disease overview and Diabetic foot ulcer treatment guidelines. The assessment part of the report embraces, in depth Diabetic foot ulcer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic foot ulcer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diabetic foot ulcer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic foot ulcer Emerging Drugs
Further product details are provided in the report..
Diabetic foot ulcer: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic foot ulcer drugs segregated based on following parameters that define the scope of the report, such as:
Diabetic foot ulcer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic foot ulcer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic foot ulcer drugs.
Diabetic foot ulcer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Diabetic foot ulcer - Pipeline Insight, 2021,” report provides comprehensive insights about 34+ companies and 34+ pipeline drugs in Diabetic foot ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Diabetic foot ulcer: Overview
A diabetic foot ulcer is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of diabetic foot ulcers requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.
'Diabetic foot ulcer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic foot ulcer pipeline landscape is provided which includes the disease overview and Diabetic foot ulcer treatment guidelines. The assessment part of the report embraces, in depth Diabetic foot ulcer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic foot ulcer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic foot ulcer R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic foot ulcer.
This segment of the Diabetic foot ulcer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic foot ulcer Emerging Drugs
- Galnobax: NovaLead Pharma
- Nemonoxacin: TaiGen Biotechnology
Further product details are provided in the report..
Diabetic foot ulcer: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic foot ulcer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic foot ulcer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Diabetic foot ulcer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic foot ulcer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic foot ulcer drugs.
Diabetic foot ulcer Report Insights
- Diabetic foot ulcer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic foot ulcer drugs?
- How many Diabetic foot ulcer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic foot ulcer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic foot ulcer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic foot ulcer and their status?
- What are the key designations that have been granted to the emerging drugs?
- NovaLead Pharma
- Helixmith
- ShangHai HaiHe Pharmaceutical
- Beyond Air
- TaiGen Biotechnology
- RHEACELL
- Technophage
- Transwell Biotech
- Roche
- Chiesi Farmaceutici
- Blue Blood Biotech
- Cynata Therapeutics
- ZZ Biotech
- APstem Therapeutics
- Lewis and Clark Pharmaceuticals
- Destiny Pharma
- SCM Lifescience
- Galnobax
- VM-202
- ON101
- Nitric oxide
- APZ2
- Nemonoxacin
- TP-102
- TWB-103
- Efmarodocokin alfa
- CHF-6467
- BB 101
- Cymerus MSC
- 3K3A-APC
- AP Skin 01
- LNC-001 therapeutics
- XF-70
- Mesenchymal stem cell therapy
Introduction
Executive Summary
Diabetic foot ulcer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Diabetic foot ulcer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetic foot ulcer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diabetic foot ulcer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Galnobax: NovaLead Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Nemonoxacin: TaiGen Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
CHF-6467: Chiesi Farmaceutici
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
AP Skin 01: APstem Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Diabetic foot ulcer Key Companies
Diabetic foot ulcer Key Products
Diabetic foot ulcer- Unmet Needs
Diabetic foot ulcer- Market Drivers and Barriers
Diabetic foot ulcer- Future Perspectives and Conclusion
Diabetic foot ulcer Analyst Views
Diabetic foot ulcer Key Companies
Appendix
Executive Summary
Diabetic foot ulcer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Diabetic foot ulcer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetic foot ulcer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diabetic foot ulcer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Galnobax: NovaLead Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Nemonoxacin: TaiGen Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
CHF-6467: Chiesi Farmaceutici
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
AP Skin 01: APstem Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Diabetic foot ulcer Key Companies
Diabetic foot ulcer Key Products
Diabetic foot ulcer- Unmet Needs
Diabetic foot ulcer- Market Drivers and Barriers
Diabetic foot ulcer- Future Perspectives and Conclusion
Diabetic foot ulcer Analyst Views
Diabetic foot ulcer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Diabetic foot ulcer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Diabetic foot ulcer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Diabetic foot ulcer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Diabetic foot ulcer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
